Dogwood Therapeutics (DWTX) Common Equity (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Common Equity of $80.9 million for Q1 2026, up 1041.86% year-over-year from $7.1 million in Q1 2025, and up 8.05% quarter-over-quarter from $74.9 million in Q4 2025.
Dogwood Therapeutics (DWTX) Common Equity (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Common Equity for 7 consecutive years, with $80.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 1041.86% year-over-year to $80.9 million; the TTM figure through Mar 2026 stood at $80.9 million (up 1041.86% YoY), while the FY2025 annual figure was $74.9 million, up 839.77% from the prior year.
- Common Equity advanced to $80.9 million in Q1 2026 per DWTX's latest filing, from $74.9 million in the prior quarter.
- Across five years, Common Equity topped out at $80.9 million in Q1 2026 and bottomed at -$10.1 million in Q4 2024.
- Historically, Common Equity has averaged $13.4 million across 5 years, with a median of $6.9 million in 2025.
- Annual changes were most pronounced in 2024 — Common Equity tumbled 365.95% — and 2026, when it surged 1041.86%.
- Dogwood Therapeutics' Common Equity stood at $7.3 million in 2022, then tumbled by 48.04% to $3.8 million in 2023, then sank by 365.95% to -$10.1 million in 2024, then surged by 839.77% to $74.9 million in 2025, then gained by 8.05% to $80.9 million in 2026.
- Business Quant data shows DWTX's Common Equity at $80.9 million in Q1 2026, $74.9 million in Q4 2025, and $7.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - | 68.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 80.92 Mn |
| Dec 31, 2025 | 74.90 Mn |
| Sep 30, 2025 | 7.26 Mn |
| Jun 30, 2025 | 6.88 Mn |
| Mar 31, 2025 | 7.09 Mn |
| Dec 31, 2024 | -10.12 Mn |
| Sep 30, 2024 | 949,431.00 |
| Jun 30, 2024 | 3.14 Mn |
| Mar 31, 2024 | 2.65 Mn |
| Dec 31, 2023 | 3.81 Mn |
| Sep 30, 2023 | 4.76 Mn |
| Jun 30, 2023 | 4.69 Mn |
| Mar 31, 2023 | 5.97 Mn |
| Dec 31, 2022 | 7.33 Mn |
| Sep 30, 2022 | 9.22 Mn |
| Jun 30, 2022 | 7.14 Mn |
| Mar 31, 2022 | 10.67 Mn |
| Dec 31, 2021 | 14.50 Mn |
| Sep 30, 2021 | 18.88 Mn |
| Jun 30, 2021 | 22.86 Mn |